3.15
7.51%
+0.22
Dopo l'orario di chiusura:
3.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
MEI Pharma Inc Borsa (MEIP) Ultime notizie
What You Need To Know About MEI Pharma, Inc.'s (NASDAQ:MEIP) Investor Composition - Yahoo Canada Shine On
Yahoo Canada Shine On
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Defense World
MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue? - Yahoo News UK
Yahoo News UK
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire
Business Wire
BAYRY: Top 4 Pharma Stocks to Consider This Month - StockNews.com
StockNews.com
MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future - Yahoo Lifestyle UK
Yahoo Lifestyle UK
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
Business Wire
Revenue Downgrade: Here's What Analysts Forecast For MEI Pharma, Inc. (NASDAQ:MEIP) - Yahoo News UK
Yahoo News UK
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4 - Yahoo Singapore News
Yahoo Singapore News
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
VTRS: 3 Pharma Stocks Outperforming the Competition - StockNews.com
StockNews.com
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Yahoo Finance
Biotech bankruptcies hit 10-year peak in 2023 - Fierce Biotech
Fierce Biotech
Is MEI Pharma (MEIP) Attractively Priced? - Yahoo Finance
Yahoo Finance
Kyowa Kirin enrols first subject in Phase II diabetic macular oedema trial - Clinical Trials Arena
Clinical Trials Arena
Fierce Biotech M&A Tracker 2023: BMS, AbbVie drop billions for neuropsychiatry biotechs - Fierce Biotech
Fierce Biotech
Infinity comes to an end with Chapter 11 bankruptcy filing - Fierce Biotech
Fierce Biotech
Anson Funds Management LP Acquires Shares in MEI Pharma Inc - Yahoo Finance
Yahoo Finance
Three execs leave Infinity Pharmaceuticals after failed merger, layoffs - The Business Journals
The Business Journals
Infinity lays off 78% of staff, 3 board members after MEI merger fails - Fierce Biotech
Fierce Biotech
Rebuffed by MEI Pharma, Infinity scuttles merger and may face bankruptcy - MM+M Online
MM+M Online
MEI Pharma Announces Results of Special Meeting of Stockholders - Business Wire
Business Wire
MEI Pharma CEO departs as company rejects unsolicited takeover bid - MM+M Online
MM+M Online
Infinity merger with MEI in doubt after surprise buyer makes bid - Fierce Biotech
Fierce Biotech
MEI Pharma Announces 1-for-20 Reverse Stock Split - Business Wire
Business Wire
Bankruptcy awaits Infinity Pharmaceuticals if MEI merger falters - MM+M Online
MM+M Online
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results - Business Wire
Business Wire
Who's gone? A snapshot of biotechs closing doors - BioCentury
BioCentury
MEI Pharma Inc Company Profile - GlobalData
GlobalData
MEI Pharma And Infinity Pharmaceuticals Announce Merger (MEIP) (INFI) - Pulse 2.0
Pulse 2.0
MEI Pharma and Infinity Pharma ink all-stock merger deal (NASDAQ:MEIP) - Seeking Alpha
Seeking Alpha
MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift - BioSpace
BioSpace
Eisai, BeiGene, Shionogi—Fierce Pharma Asia - FiercePharma
FiercePharma
The Top 25 Healthcare Technology Leaders of San Diego for 2022 - The Healthcare Technology Report.
The Healthcare Technology Report.
40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswire
GlobeNewswire
MEI Pharma stock trades higher as FY22 revenue grows 17% - Seeking Alpha
Seeking Alpha
Vertex's Hughes moves to Teva - BioCentury
BioCentury
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid ... - BioSpace
BioSpace
PI3K inhibitor survival data raise cancer trial design questions - BioCentury
BioCentury
FDA Informs Developers of Zandelisib of Need for Randomized Phase 3 Trial for Approval - Cancer Network
Cancer Network
Those who invested in MEI Pharma (NASDAQ:MEIP) five years ago are up 62% - Yahoo Canada Finance
Yahoo Canada Finance
MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of ... - Business Wire
Business Wire
MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Mei (MEIP) Begins Phase III Study for B-Cell Malignancies - Yahoo Singapore News
Yahoo Singapore News
MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences - PR Newswire
PR Newswire
MEI Pharma Set To Explode With Announcement Of Lucrative Partnership (NASDAQ:MEIP) - Seeking Alpha
Seeking Alpha
MEI Pharma Announces Pricing of Public Offering of Common Stock - PR Newswire
PR Newswire
MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib - PR Newswire
PR Newswire
Capitalizzazione:
|
Volume (24 ore):